Developer docs
API playgroundTry for free, no card

Search company profiles

Medac Pharma

Full company profile

uuid000bxog

Namestring
Medac Pharma
Legal namestring
medac Pharma LLP
Company typeenum
Private
Founded yearint
1970
Descriptiontext

medac Pharma is the UK operating subsidiary of medac GmbH, a privately-held German pharmaceutical company founded in 1970 in Wedel near Hamburg. The group employs over 2,000 people worldwide and distributes a portfolio of generics, biosimilars, original products, diagnostics and cell therapies across 91 countries, with primary therapeutic focus on rheumatology, urology, haematology and oncology. Manufacturing is vertically integrated through ONCOTEC Pharma Produktion GmbH in Dessau-Roßlau (cytostatics) and oncomed manufacturing a.s. in Brno (production and logistics), with UK operations based at Scion House, Stirling University Innovation Park. The company also operates a CDMO business providing aseptic processing of injectables, sterile manufacturing and technology transfer to pharmaceutical and biotech partners under FDA, ANVISA and PMDA compliant frameworks.

Core proprietary technology assets include the closed instillation system pioneered in 1988 for non-muscle invasive bladder cancer treatment, now regarded as a global gold standard, and proprietary conditioning therapy for allogeneic stem cell transplantation that expanded treatment eligibility to elderly, co-morbid and pediatric patients. medac is a recognised leading supplier of subcutaneous methotrexate for autoimmune diseases and produces chemotherapy agents (Doxorubicin, Epirubicin, Dacarbazine, Carmustine), BCG-medac for bladder cancer, and a growing biosimilar portfolio. FY 2023/24 output reached 48 million units assembled and packaged, including 9 million pens and 10 million syringes, with a 98% average delivery capability since 2021.

The business model is primarily product-driven: pharmaceutical sales to healthcare institutions and professionals (oncologists, urologists, rheumatologists, haematologists) routed through wholly-owned subsidiaries and branch offices across Europe, Japan and the UAE. A secondary revenue stream consists of contract development and manufacturing services for external pharma and biotech partners requiring aseptic injectable fill-finish. Pricing is not publicly disclosed, consistent with prescription-based institutional sales channels, and the company pursues a value-oriented, long-term management strategy emphasising reliable supply and unmet therapeutic need rather than direct-to-consumer marketing.

Short descriptiontext

Medac Pharma is the UK subsidiary of privately-held German pharmaceutical company medac GmbH, distributing generics, biosimilars, cell therapies and diagnostics across 91 countries with focus on rheumatology, urology, haematology and oncology, and operating a CDMO business.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStirling, United Kingdom
HQ citystring
Stirling
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices16 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, oncology therapeutics, autoimmune disease treatments, aseptic injectable manufacturing, contract development manufacturing
Industry4 codes
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Sales of proprietary pharmaceutical products including generics, original products, and biosimilars in the therapeutic areas of rheumatology, urology, haematology, and oncology. Products are distributed to 91 countries worldwide.

medacpharma.co.uk
2CDMO Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization services offering aseptic processing of injectables, sterile manufacturing, and technology transfer for clinical and commercial sectors globally. Partners include start-ups, biotech and pharmaceutical companies.

medacpharma.co.uk
3Diagnostics
TypeOne Time License
Description

Development and distribution of diagnostics products alongside pharmaceutical products.

medacpharma.co.uk
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1BCG-medac
Description

Contains Bacillus Calmette Guérin, available as powder and solvent for intravesical suspension, used for bladder cancer treatment.

medacpharma.co.uk
+4 more records
Core offering1 text field

Medac Pharma develops, manufactures, and distributes proprietary pharmaceutical products — including generics, biosimilars, cell therapies, and original products — across four therapeutic areas: rheumatology, urology, haematology, and oncology. The company supplies prescription products to healthcare professionals and institutions in 91 countries, and operates CDMO services offering aseptic injectable manufacturing and technology transfer to pharmaceutical and biotech partners. Manufacturing is conducted in Germany and the Czech Republic under European quality standards.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 98% delivery capability maintained (average since 2021)
+3 more records
Product overview1 text field

Medac Pharma is a pharmaceutical company with a diverse portfolio spanning four therapeutic focus areas: rheumatology, urology, oncology, and haematology. The company offers original products, generics, and biosimilars as well as diagnostics. Key products include BCG-medac for bladder cancer treatment, methotrexate for autoimmune diseases, and cell therapy products for stem cell transplantation. Medac also operates as a CDMO (Contract Development and Manufacturing Organization) providing sterile injectable manufacturing services. The product portfolio includes chemotherapy agents (Doxorubicin, Epirubicin, Dacarbazine, Carmustine), immunotherapies (BCG-medac), and biosimilars, with manufacturing capabilities through subsidiaries oncotec GmbH and oncomed a.s.

Product and service9 records
1BCG-medac
CategoryUrology pharmaceuticals
Description

Pharmaceutical product containing Bacillus Calmette Guérin available as powder and solvent for intravesical suspension, used for the treatment of non-muscle invasive bladder cancer (NMIBC) via medac's proprietary closed instillation system.

2Carmustine medac
CategoryHaematology pharmaceuticals
Description

Powder and solvent for concentrate for solution for infusion used in haematology, with marketing authorisation transferred from Obvius to medac.

3Dacarbazine
CategoryOncology pharmaceuticals
Description

Powder for solution for injection or infusion used in oncology treatments.

4Doxorubicin
CategoryOncology pharmaceuticals
Description

Solution for infusion used in oncology treatments.

5Epirubicin
CategoryOncology pharmaceuticals
Description

Solution for injection used in oncology treatments.

6Methotrexate
CategoryRheumatology pharmaceuticals
Description

Crucial drug in the treatment of autoimmune diseases including rheumatic diseases, with medac recognised as a leading supplier of subcutaneous methotrexate and continuous improvement of delivery systems.

7Cell Therapy Products
CategoryHaematology pharmaceuticals
Description

Products for cell therapy, particularly used in conditioning therapy prior to allogeneic stem cell transplantation for haematological diseases in children and adults, providing access for patient groups previously ineligible including elderly and co-morbid patients.

8Biosimilars
CategoryRheumatology pharmaceuticals
Description

Biosimilar products for the treatment of autoimmune diseases, forming part of medac's strategic expansion of their biosimilar niche portfolio.

9CDMO Services
CategoryContract manufacturing services
Description

Contract Development and Manufacturing Organization services offering aseptic processing of injectables, sterile manufacture of medicinal products, formulation and filling of sterile injectables for clinical and commercial sectors. Services include technology transfer, regulatory compliance support (FDA, ANVISA, PMDA), and a modular cooperation model for pharmaceutical, biotech, and start-up partners.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Start-ups, Biotech and Pharmaceutical Companies
Strategic tierCoreTypeStrategic or Co-development Partner
Description

medac offers a modular cooperation model for pharmaceutical partnerships ranging from full product development to final approval steps. Services include strategic planning, targeted due diligence, gap analyses, comprehensive product development plans, and access to an established network of key opinion leaders, academics, non-profit organisations, experts and patient representatives.

medacpharma.co.uk
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German-based private specialty pharma offering generics, biosimilars, and consumer health products across Europe with a comparable CDMO-style manufacturing footprint. Closest match in size, geography, and product mix to medac.

TypeDirect peer
Description

UK-listed specialty pharma focused on generic injectables, biosimilars, and branded products, with strong manufacturing capabilities and CDMO services — highly comparable to medac's injectable and biosimilar portfolio.

TypeDirect peer
Description

South African specialty pharma with global generics, biosimilars, and sterile injectable manufacturing operations, serving oncology and autoimmune indications. Comparable therapeutic-area focus and CDMO exposure.

TypeDirect peer
Description

India-based generics and injectables manufacturer with growing CDMO business and biosimilar pipeline. Comparable product mix in cytostatics and sterile injectables, though at significantly larger scale.

TypeDirect peer
Description

Swiss CDMO with both API and drug product manufacturing for small-molecule generics and innovative pharma partners. Comparable CDMO service model and European manufacturing footprint.

TypeBroad incumbent
Description

Global generics and biosimilars major formed from Mylan and Upjohn, with broad portfolio across therapeutic areas including oncology and autoimmune. Significantly larger than medac but competes in the same generic injectable and biosimilar segments.

TypeBroad incumbent
Description

World's largest generic drug manufacturer with significant biosimilar pipeline and injectable capabilities. Competes with medac across multiple therapeutic areas and geographies.

TypeBroad incumbent
Description

Major global CDMO offering sterile injectable fill-finish, biologics, and oral dose manufacturing. Directly comparable CDMO service portfolio though at significantly larger scale.

TypeDirect peer
Description

India-based generics manufacturer with growing biosimilar and CDMO business, including sterile injectables and oncology products. Comparable product mix and growing European footprint.

TypeRegional player
Description

Spanish specialty pharma focused on dermatology and specialty therapeutic areas with European commercial footprint. Comparable mid-cap European specialty pharma profile though different therapeutic focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks8 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medac Pharma

Specialty Pharmaceuticalsmedacpharma.co.uk

Medac Pharma is the UK subsidiary of privately-held German pharmaceutical company medac GmbH, distributing generics, biosimilars, cell therapies and diagnostics across 91 countries with focus on rheumatology, urology, haematology and oncology, and operating a CDMO business.

What Medac Pharma does

medac Pharma is the UK operating subsidiary of medac GmbH, a privately-held German pharmaceutical company founded in 1970 in Wedel near Hamburg. The group employs over 2,000 people worldwide and distributes a portfolio of generics, biosimilars, original products, diagnostics and cell therapies across 91 countries, with primary therapeutic focus on rheumatology, urology, haematology and oncology. Manufacturing is vertically integrated through ONCOTEC Pharma Produktion GmbH in Dessau-Roßlau (cytostatics) and oncomed manufacturing a.s. in Brno (production and logistics), with UK operations based at Scion House, Stirling University Innovation Park. The company also operates a CDMO business providing aseptic processing of injectables, sterile manufacturing and technology transfer to pharmaceutical and biotech partners under FDA, ANVISA and PMDA compliant frameworks.

Core proprietary technology assets include the closed instillation system pioneered in 1988 for non-muscle invasive bladder cancer treatment, now regarded as a global gold standard, and proprietary conditioning therapy for allogeneic stem cell transplantation that expanded treatment eligibility to elderly, co-morbid and pediatric patients. medac is a recognised leading supplier of subcutaneous methotrexate for autoimmune diseases and produces chemotherapy agents (Doxorubicin, Epirubicin, Dacarbazine, Carmustine), BCG-medac for bladder cancer, and a growing biosimilar portfolio. FY 2023/24 output reached 48 million units assembled and packaged, including 9 million pens and 10 million syringes, with a 98% average delivery capability since 2021.

The business model is primarily product-driven: pharmaceutical sales to healthcare institutions and professionals (oncologists, urologists, rheumatologists, haematologists) routed through wholly-owned subsidiaries and branch offices across Europe, Japan and the UAE. A secondary revenue stream consists of contract development and manufacturing services for external pharma and biotech partners requiring aseptic injectable fill-finish. Pricing is not publicly disclosed, consistent with prescription-based institutional sales channels, and the company pursues a value-oriented, long-term management strategy emphasising reliable supply and unmet therapeutic need rather than direct-to-consumer marketing.

Medac Pharma firmographics

Firmographics
Name
Medac Pharma
Legal name
medac Pharma LLP
Website
https://medacpharma.co.uk
Company type
Private
Founded year
1970
Operating status
Operating
Headcount range
11–50 employees
Short description
Medac Pharma is the UK subsidiary of privately-held German pharmaceutical company medac GmbH, distributing generics, biosimilars, cell therapies and diagnostics across 91 countries with focus on rheumatology, urology, haematology and oncology, and operating a CDMO business.
Ownership category
akta.pro rank

Medac Pharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Specialty pharmaceuticals
  • Oncology therapeutics
  • Autoimmune disease treatments
  • Aseptic injectable manufacturing
  • Contract development manufacturing

Where Medac Pharma is headquartered

Location

Headquarters

HQ city
Stirling
HQ country
United Kingdom
HQ region
Europe

Offices16 records

Markets served

Medac Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical Product Sales: Sales of proprietary pharmaceutical products including generics, original products, and biosimilars in the therapeutic areas of rheumatology, urology, haematology, and oncology. Products are distributed to 91 countries worldwide.
  2. CDMO Services: Contract Development and Manufacturing Organization services offering aseptic processing of injectables, sterile manufacturing, and technology transfer for clinical and commercial sectors globally. Partners include start-ups, biotech and pharmaceutical companies.
  3. Diagnostics: Development and distribution of diagnostics products alongside pharmaceutical products.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Medac Pharma product offering

Product offering

Core offering

Medac Pharma develops, manufactures, and distributes proprietary pharmaceutical products — including generics, biosimilars, cell therapies, and original products — across four therapeutic areas: rheumatology, urology, haematology, and oncology. The company supplies prescription products to healthcare professionals and institutions in 91 countries, and operates CDMO services offering aseptic injectable manufacturing and technology transfer to pharmaceutical and biotech partners. Manufacturing is conducted in Germany and the Czech Republic under European quality standards.

Product overview

Medac Pharma is a pharmaceutical company with a diverse portfolio spanning four therapeutic focus areas: rheumatology, urology, oncology, and haematology. The company offers original products, generics, and biosimilars as well as diagnostics. Key products include BCG-medac for bladder cancer treatment, methotrexate for autoimmune diseases, and cell therapy products for stem cell transplantation. Medac also operates as a CDMO (Contract Development and Manufacturing Organization) providing sterile injectable manufacturing services. The product portfolio includes chemotherapy agents (Doxorubicin, Epirubicin, Dacarbazine, Carmustine), immunotherapies (BCG-medac), and biosimilars, with manufacturing capabilities through subsidiaries oncotec GmbH and oncomed a.s.

Differentiator

Problem solved

Functional benefit

Brands

  • BCG-medac: Contains Bacillus Calmette Guérin, available as powder and solvent for intravesical suspension, used for bladder cancer treatment.
  • Carmustine medac
  • Dacarbazine
  • Doxorubicin
  • Epirubicin

Products and services

  • BCG-medac Pharmaceutical product containing Bacillus Calmette Guérin available as powder and solvent for intravesical suspension, used for the treatment of non-muscle invasive bladder cancer (NMIBC) via medac's proprietary closed instillation system.
  • Carmustine medac Powder and solvent for concentrate for solution for infusion used in haematology, with marketing authorisation transferred from Obvius to medac.
  • Dacarbazine Powder for solution for injection or infusion used in oncology treatments.
  • Doxorubicin Solution for infusion used in oncology treatments.
  • Epirubicin Solution for injection used in oncology treatments.
  • Methotrexate Crucial drug in the treatment of autoimmune diseases including rheumatic diseases, with medac recognised as a leading supplier of subcutaneous methotrexate and continuous improvement of delivery systems.
  • Cell Therapy Products Products for cell therapy, particularly used in conditioning therapy prior to allogeneic stem cell transplantation for haematological diseases in children and adults, providing access for patient groups previously ineligible including elderly and co-morbid patients.
  • Biosimilars Biosimilar products for the treatment of autoimmune diseases, forming part of medac's strategic expansion of their biosimilar niche portfolio.
  • CDMO Services Contract Development and Manufacturing Organization services offering aseptic processing of injectables, sterile manufacture of medicinal products, formulation and filling of sterile injectables for clinical and commercial sectors. Services include technology transfer, regulatory compliance support (FDA, ANVISA, PMDA), and a modular cooperation model for pharmaceutical, biotech, and start-up partners.

Quantifiable outcome

  • 98% delivery capability maintained (average since 2021)
  • +3 more outcomes

Companies that use Medac Pharma

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Medac Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Medac Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Start-ups, Biotech and Pharmaceutical CompaniescoreStrategic or Co-development Partnermedac offers a modular cooperation model for pharmaceutical partnerships ranging from full product development to final approval steps. Services include strategic planning, targeted due diligence, gap analyses, comprehensive product development plans, and access to an established network of key opinion leaders, academics, non-profit organisations, experts and patient representatives.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Medac Pharma competitors and assessment

Company assessment

Direct peers

  • Stada Arzneimittel: German-based private specialty pharma offering generics, biosimilars, and consumer health products across Europe with a comparable CDMO-style manufacturing footprint. Closest match in size, geography, and product mix to medac.
  • Hikma Pharmaceuticals: UK-listed specialty pharma focused on generic injectables, biosimilars, and branded products, with strong manufacturing capabilities and CDMO services — highly comparable to medac's injectable and biosimilar portfolio.
  • Aspen Pharmacare: South African specialty pharma with global generics, biosimilars, and sterile injectable manufacturing operations, serving oncology and autoimmune indications. Comparable therapeutic-area focus and CDMO exposure.
  • Aurobindo Pharma: India-based generics and injectables manufacturer with growing CDMO business and biosimilar pipeline. Comparable product mix in cytostatics and sterile injectables, though at significantly larger scale.
  • Siegfried Holding: Swiss CDMO with both API and drug product manufacturing for small-molecule generics and innovative pharma partners. Comparable CDMO service model and European manufacturing footprint.
  • Dr. Reddy's Laboratories: India-based generics manufacturer with growing biosimilar and CDMO business, including sterile injectables and oncology products. Comparable product mix and growing European footprint.

Broad incumbents

  • Viatris: Global generics and biosimilars major formed from Mylan and Upjohn, with broad portfolio across therapeutic areas including oncology and autoimmune. Significantly larger than medac but competes in the same generic injectable and biosimilar segments.
  • Teva Pharmaceutical Industries: World's largest generic drug manufacturer with significant biosimilar pipeline and injectable capabilities. Competes with medac across multiple therapeutic areas and geographies.
  • Catalent: Major global CDMO offering sterile injectable fill-finish, biologics, and oral dose manufacturing. Directly comparable CDMO service portfolio though at significantly larger scale.

Regional players

  • Almirall: Spanish specialty pharma focused on dermatology and specialty therapeutic areas with European commercial footprint. Comparable mid-cap European specialty pharma profile though different therapeutic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks8 records

Key highlights6 records

Customer concentration

Medac Pharma social profiles

Digital presence

Medac Pharma compliance and trust

Trust signal

Compliance5 records

Medac Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medac Pharma leadership team

Management profile

Number of profiles

Profiles4 records

Medac Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Medac Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medac Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medac Pharma

What does Medac Pharma do?

Medac Pharma develops, manufactures, and distributes proprietary pharmaceutical products — including generics, biosimilars, cell therapies, and original products — across four therapeutic areas: rheumatology, urology, haematology, and oncology. The company supplies prescription products to healthcare professionals and institutions in 91 countries, and operates CDMO services offering aseptic injectable manufacturing and technology transfer to pharmaceutical and biotech partners. Manufacturing is conducted in Germany and the Czech Republic under European quality standards.

Is Medac Pharma a public or private company?

Medac Pharma is a private company. It is classified as corporate owned and is currently operating.

When was Medac Pharma founded?

Medac Pharma was founded in 1970. It employs 11 to 50 people.

Where is Medac Pharma based?

Medac Pharma is headquartered in Stirling, United Kingdom, in the Europe region.

How does Medac Pharma make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are CDMO Services and diagnostics.

Who are Medac Pharma's main competitors?

Direct peers on record are Stada Arzneimittel, Hikma Pharmaceuticals, Aspen Pharmacare, Aurobindo Pharma, Siegfried Holding and Dr. Reddy's Laboratories. Broad incumbents are Viatris, Teva Pharmaceutical Industries and Catalent. Almirall is listed as a regional player.

Does Medac Pharma have an API?

No public API is recorded for Medac Pharma.

What industry is Medac Pharma in?

Medac Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals